Clinical Cancer Research CTRC-AACR San Antonio Breast Cancer Symposium Translational Cancer Medicine 2008: Cancer Clinical Trials and Personalized Medicine
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Cell Growth & Differentiation
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lawrence, T. S.
Right arrow Articles by Rehemtulla, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lawrence, T. S.
Right arrow Articles by Rehemtulla, A.
Related Collections
Right arrowCommentary
Clinical Cancer Research Vol. 7, 314-319, February 2001
© 2001 American Association for Cancer Research

Experimental Therapeutics, Preclinical Pharmacology

The Role of Apoptosis in 2',2'-Difluoro-2'-deoxycytidine (Gemcitabine)-mediated Radiosensitization1

Theodore S. Lawrence2, Mary A. Davis, Amanda Hough and Alnawaz Rehemtulla

Department of Radiation Oncology, University of Michigan Medical Center, Ann Arbor, Michigan 48109-0582


   ABSTRACT
Top
 ABSTRACT
INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 
The nucleoside analogue Gemcitabine [2',2'-difluoro-2'-deoxycytidine (dFdCyd)] is active against a wide variety of solid tumors and is a potent radiation sensitizer. Because apoptosis has been shown to be an important mechanism of cell death for many cancers, we wished to investigate the role of apoptosis in dFdCyd-mediated radiosensitization. We evaluated HT29 colon cancer cells, UMSCC-6 head and neck cancer cells, and A549 lung cancer cells, which differ substantially in the ability to undergo radiation-induced apoptosis. We hypothesized that if dFdCyd produced radiosensitization by potentiating preexisting death pathways, then only the apoptotic-prone HT29 cells would show a substantial increase in apoptosis when treated with the combination of dFdCyd and radiation and that UMSCC-6 cells and A549 cells would be radiosensitized through nonapoptotic mechanisms. We found that the radiosensitization of HT29 cells (enhancement ratio, 1.81 ± 0.16) was accompanied by an increase in apoptosis and by caspase activation and that inhibition of this activation by the caspase inhibitor Z-Asp-Glu-Val-Asp-fluoromethylketone (DEVD) significantly decreased radiosensitization (to 1.36 ± 0.24; P < 0.05). In contrast, UMSCC-6 cells and A549 cells were modestly radiosensitized (enhancement ratio, 1.47 ± 0.24 and 1.31 ± 0.04, respectively) via a nonapoptotic mechanism. These findings suggest that although apoptosis can contribute significantly to dFdCyd-mediated radiosensitization, the role of apoptosis in dFdCyd-mediated radiosensitization depends on the cell line rather than representing a general property of the drug.


   INTRODUCTION
Top
 ABSTRACT
 INTRODUCTION
MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 
The nucleoside analogue dFdCyd3 has shown promising clinical effectiveness against a range of solid tumors, most importantly non-small cell lung cancer and pancreatic cancer, and has been shown both in laboratory and clinical studies to be a potent radiation sensitizer (reviewed in Refs. 1, 2, 3, 4 ). We have shown that sensitization in log phase cells occurs under treatment conditions that produce simultaneous cell cycle redistribution of cells into S phase and depletion of intracellular dATP pools. However, the mechanism of sensitization remains unclear.

We wished to determine whether dFdCyd affected radiation-induced apoptosis. There is substantial evidence that chemotherapeutic drugs, including dFdCyd (5) , can activate the cellular apoptotic machinery, and that alterations in the expression of pro- and antiapoptotic proteins directly affect the sensitivity of cancer cells to chemotherapy (6, 7, 8) . Activation of the apoptotic machinery in response to a variety of cellular stresses and physiological stimuli culminates in the activation of a family of cysteine proteases with specificity for aspartic acid residues (Caspases). Upon activation, caspases initiate cleavage of a number of essential cellular polypeptides (e.g., lamins, (poly)ADP ribose polymerase, actin, and so forth) resulting in cell death. Cleavage of these "death substrates" as well as cleavage of chromosomal DNA results in morphological changes, such as nuclear condensation, loss of cell shape, and cytoplasmic shrinkage and fragmentation of the nucleus, which are characteristic of apoptotic cells (9 , 10) .

To begin to determine the role of apoptosis in dFdCyd-mediated radiosensitization, we assessed the effect of dFdCyd on the radiation sensitivity of three cell lines that differ substantially in their propensity to undergo radiation-induced apoptosis: HT29 human colon cancer cells, UMSCC-6 (head and neck) squamous cancer cells, and A549 lung cancer cells. Under the conditions used in this study, a relatively high fraction of clonogenic death from radiation is attributable to apoptosis in HT29 cells, whereas apoptosis plays less of a role in the overall clonogenic death of UMSCC-6 and A549 cells. If dFdCyd radiosensitized solely by increasing apoptosis, we would predict that all three of the cell types would show increased apoptosis in proportion to radiosensitization. In contrast, if dFdCyd produced radiosensitization by potentiating preexisting death pathways, then we would predict that only the apoptosis-prone HT29 cells would show a substantial increase in apoptosis when treated with the combination of dFdCyd and radiation, and that UMSCC-6 cells and A549 cells would be radiosensitized through nonapoptotic mechanisms. When we found that the latter was the case, we determined whether this increased apoptosis in HT29 cells was accompanied by an increase in caspase activation and whether inhibition of this activation could decrease radiosensitization.


   MATERIALS AND METHODS
Top
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
RESULTS
 DISCUSSION
 REFERENCES
 
Cell Culture and Clonogenic Assay.
Cell lines were cultured under standard conditions using RPMI medium, as described previously (11) . Two days prior to drug addition, cells were released from the flasks with PBS containing 0.03% trypsin and 0.27 mM EDTA and plated into 100-mm culture dishes. This procedure results in log-phase cells at the time of drug addition. Cells were checked for Mycoplasma every 3 months. Clonogenic survival was assessed using a standard clonogenic assay, as described previously (11) . Radiation survival data from drug-treated cells were corrected for plating efficiency using an unirradiated plate treated with drug under the same conditions. Cell survival curves were fitted using the linear-quadratic equation, and the mean inactivation dose was calculated according to the method of Fertil et al. (12) . The cell survival enhancement ratio was calculated as the ratio of the mean inactivation dose under control conditions divided by the mean inactivation dose after drug exposure.

Caspase 3 Activation.
Caspase 3 activity was measured fluorometrically in cell lysates, as recommended by the manufacturer (Enzyme Systems Products, Livermore, CA) using an artificial substrate (AFC-138) that fluoresces when it is cleaved (excitation at 400 nm, emission at 505 nm).

Irradiation.
Cells were irradiated using 60Co at 1–2 Gy/min. Dosimetry was carried out using an ionization chamber connected to an electrometer system that is directly traceable to a National Institute of Standards and Technology calibration.

Apoptosis.
The apoptotic fraction was calculated by taking the ratio of floating cells:total cell number (floating plus adherent). This assay was validated by demonstrating that >90% of the floating cells were morphologically apoptotic by propidium iodide staining (see "Results"). The scoring of floating cells as apoptotic was further validated by gel electrophoresis. For this assay, cells were lysed, and treated with RNase and proteinase K. The DNA was precipitated with isopropanol, dried, resuspended in Tris/EDTA, and electrophoresed in a 0.75% agarose gel at 120 V for 10 min. followed by 90 V for 60 min. Bands were visualized using ethidium bromide staining. This method of DNA preparation does not recover total cellular DNA; rather it detects soluble (fragmented) DNA (see "Results"). A 1-kb DNA ladder was used as a standard.

Statistics.
Unless otherwise indicated, all of the data are presented as the mean ± SE of at least three experiments. Student’s t test was used to compare two means. Statistical significance was defined at the level of P < 0.05.


   RESULTS
Top
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
DISCUSSION
 REFERENCES
 
We began these studies by determining whether the fraction of floating cells could be used as a marker for apoptosis. HT29 cells were exposed to 10 nM dFdCyd for 24 h, the drug was washed away, and the cellular morphology of floating and adherent cells was assessed 3 days later using propidium iodide staining (Fig. 1)Citation . We found that essentially all of the adherent cells had normal nuclear morphology, whereas virtually all of the floating cells showed nuclear fragmentation (reviewed in Refs. 13 and 14 ). Identical results were obtained with UMSCC-6 and A549 cells (data not shown), although in the latter cell line, very few floating cells were observed. To confirm that these morphological changes reflected apoptosis, we used agarose gel electrophoresis, as described in "Materials and Methods," to detect DNA fragmentation in cells treated with dFdCyd. We found substantial DNA fragmentation in HT29 cells, moderate fragmentation in UMSCC-6 cells, and little fragmentation in A549 cells (Fig. 2)Citation . These findings suggested that we could use the fraction of floating cells to quantify apoptosis and began to suggest that dFdCyd treatment increased radiation-induced apoptosis in HT29 cells, but less so in UMSCC-6 cells and A549 cells.



View larger version (16K):
[in this window]
[in a new window]
  		Fig. 1. Use of floating cells to assess apoptosis. Adherent (left) and floating (right) Gemcitabine-treated HT29 cells were stained with propidium iodide and assessed for morphological evidence of apoptosis.

 


View larger version (117K):
[in this window]
[in a new window]
  		Fig. 2. Use of agarose gel electrophoresis to assess apoptosis. After drug and/or radiation treatment as described in the text, HT29, UMSCC-6 cells, and A549 cells were lysed and treated as described in "Materials and Methods." A B-cell lymphoma-derived cell line, BJAB, which is highly prone to apoptosis, was used as a positive control. A 1-kb DNA ladder was used as a standard.

 
We then quantified the effect of radiation, in the absence and presence of dFdCyd, on the extent of apoptosis. When HT29 cells, UMSCC-6 cells, and A549 cells were exposed to 10 nM dFdCyd for 24 h, followed by radiation, all of the three cell lines showed radiosensitization (Fig. 3Citation ; Table 1Citation ) with an enhancement ratio of 1.81 ± 0.16, 1.47 ± 0.24, and 1.31 ± 0.04, respectively. Radiosensitization of HT29 cells was significantly greater than that of A549 cells (P < 0.05) and tended to be greater than that of UMSCC-6 cells (P = 0.10), although the latter comparison did not reach statistical significance. Radiosensitization in all of the three cell lines was related more to a change in the {alpha} component (the low dose or "shoulder" region) of the survival curve than to the ß component.



View larger version (20K):
[in this window]
[in a new window]
  		Fig. 3. Effect of dFdCyd on radiation sensitivity of HT29, UMSCC-6, and A549 cells. Cells were treated with 10 nM dFdCyd for 24 h. They were then irradiated, the drug removed, and the media replaced with fresh media. The cultures were returned to the incubator for 72 h (HT29) or 96 h (UMSCC-6 and A549), after which they were processed for clonogenicity.

 

View this table:
[in this window]
[in a new window]
  		Table 1 Effects of dFdCyd on radiosensitivity in HT29, UMSCC-6, and A549 cells

 
We then quantified the fraction of apoptotic cells after varying doses of radiation in the presence or absence of dFdCyd under the same conditions under which we measured radiosensitization. We chose doses of radiation that produced approximately the same clonogenic survival (10 and 1%) in the three cell lines. We found that apoptosis after radiation alone, dFdCyd alone, and the combination, was greatest in HT29 cells, intermediate in UMSCC-6 cells, and least in A549 cells (Fig. 4)Citation . To quantify the contribution of apoptosis to overall clonogenic death, we determined the fraction of cell death attributable to apoptosis under these conditions for these three cell lines (Table 2)Citation . This analysis confirmed that the order of importance of apoptosis in clonogenic survival is HT29 > UMSCC-6 > A549.



View larger version (22K):
[in this window]
[in a new window]
  		Fig. 4. Effect of dFdCyd on radiation- induced apoptosis of HT29, UMSCC-6, and A549 cells. Cells were treated with 10 nM dFdCyd for 24 h prior to irradiation, after which the drug was removed and the cells returned to the incubator for 72 h before assessment of the apoptosis as described in "Materials and Methods." Note the scale of the Y axis differs for HT29 cells compared with the other two cell lines.

 

View this table:
[in this window]
[in a new window]
  		Table 2 Fraction (%) of clonogenic death attributable to apoptosis after treatment with radiation, dFdCyd, or the combination, in HT29 cells, UMSCC-6 cells, and A549 cells

 
To better characterize the effect of radiation and dFdCyd on apoptotic pathways, we measured caspase 3 activation beginning 1–2 days after treatment using the dose of radiation that produced 10% surviving fraction. (These conditions permitted us to determine activation prior to the morphological appearance of apoptosis.) We found a dramatic increase in caspase activation by radiation (in the presence or absence of dFdCyd) in HT29 cells, whereas there were only marginal increases in caspase activation in UMSCC-6 and A549 cells (Fig. 5)Citation .



View larger version (16K):
[in this window]
[in a new window]
  		Fig. 5. Effect of dFdCyd and radiation on caspase 3 activation. Cells were treated with 10 nM dFdCyd and irradiated with a dose predicted to produce a surviving fraction of 10% when administered alone (4 Gy, 3 Gy, and 3 Gy for HT29, UMSCC-6, and A549 cells, respectively). Two to 4 days later, they were assessed for caspase 3 activation as described in "Materials and Methods." Data are expressed as a fraction of caspase activity compared with untreated cells. Note the scale of the Y axis differs for HT29 cells compared with the other two cell lines.

 
These data indirectly supported our hypothesis that apoptosis plays an important role in radiosensitization of HT29 cells, as opposed to UMSCC-6 and A549 cells. To assess directly the role of apoptosis in radiosensitization, we treated HT29 cells with the caspase 3 inhibitor DEVD (2 µM) beginning 4 h prior to the initiation of dFdCyd treatment and continuing after combined treatment with dFdCyd (10 nM) and radiation (7 Gy). We found that DEVD significantly reduced apoptosis produced by the combination of dFdCyd and radiation (by 24 ± 8%). Furthermore, DEVD, used under the same conditions that decreased apoptosis, significantly decreased dFdCyd-mediated radiosensitization in HT29 cells, with a resulting enhancement ratio of 1.36 ± 0.24. In contrast, neither 2 µM zVAD (a more general inhibitor of caspases) nor DEVD, at concentrations of between 0.5 and 4 µM, had an effect on the radiation sensitivity (in the presence or absence of dFdCyd) of UMSCC-6 cells and A549 cells (data not shown).


   DISCUSSION
Top
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
REFERENCES
 
In this study, we have found that apoptosis plays an important role in dFdCyd-mediated radiosensitization of HT29 cells, but not of UMSCC-6 and A549 cells. The importance of apoptosis in dFdCyd-mediated radiosensitization of HT29 cells is suggested by our findings that apoptosis is responsible for a high fraction of overall clonogenic cell death, and that the inhibition of caspase activation significantly reduces radiosensitization. However, our findings also demonstrate that the stimulation of apoptosis is not the only mechanism responsible for radiosensitization, based on the findings that UMSCC-6 and A549 cells are sensitized with modest-to-minimal apoptosis, and that zVAD reduces, but does not eliminate, sensitization in HT29 cells.

The significance of apoptosis in the response to radiation therapy (with or without radiation sensitizers) is controversial. Although some investigators have correlated the ability to undergo apoptosis with response, several recent reviews have summarized findings that suggest that apoptosis is, in some cases, only a minor component of overall clonogenic death (15 , 16) . Our findings suggest that the role of apoptosis in dFdCyd-mediated radiosensitization depends on the cell line and does not represent a general property of the drug. We also found that dFdCyd alone causes apoptosis to varying degrees in these three cell lines derived from solid tumors. Gemcitabine alone causes substantial apoptosis in leukemia cells (17) , further supporting the cell type dependence of the response.

A limitation of this study is that we investigated only the terminal parts of the apoptotic pathway (caspase 3 activation and morphological changes). Apoptosis can result from the activation of several upstream pathways, including ceramide production, tumor necrosis factor receptor simulation (18 , 19) , and mitochondrial release of cytochrome C (20) . We chose to investigate only the final common pathways to assess the overall potential importance of apoptosis. Our findings suggest that it might be worthwhile to determine which of these pathways is activated, because it remains possible that selective potentiation of the active pathway could increase the effectiveness of dFdCyd as a radiation sensitizer in some cell types.

Previous studies have suggested that dFdCyd-mediated radiosensitization depends on the simultaneous depletion of dATP pools and the redistribution of cells into S phase (21 , 22) . This condition affects neither radiation-induced DNA damage nor the repair of damage, as assessed by pulsed field gel electrophoresis (22) . It seems possible that dFdCyd-perturbed nucleotide pools produce misrepair after radiation that is not detectable at the level of pulsed-field gel electrophoresis. Present studies are directed toward elucidating this potential defect.

An initial goal of this work was to develop a predictive assay for determining which patients might benefit from dFdCyd-mediated radiosensitization. Our findings suggest that, although apoptosis may play a role in radiosensitization, it might not be possible to base the assessment on this single factor. Likewise, p53 status alone does not seem to predict radiosensitization in RKO colon cancer cells (23) , further supporting the concept that single gene or pathway alterations are unlikely to explain radiosensitization across multiple cell lines. It is hoped that developments in microarray technology will permit simultaneous assessment of multiple pathways that will permit a broader view of cellular responses than can be determined using more traditional approaches. In addition, the usefulness of dFdCyd as a clinical radiosensitizer depends not only on the tumor response but also on the normal tissue response. For instance, clinical trials have demonstrated that doses of dFdCyd as low as 50 mg/m2 administered weekly through a course of fractionated radiation for patients with head and neck cancer can produce unacceptable toxicity in the oral mucosa (24) , whereas a much higher dose of dFdCyd (600 mg/m2) is tolerable for patients undergoing a standard course of radiation for pancreatic cancer (25) . There is a critical need for improved models for both tumor control and normal tissue toxicity to help improve our ability to predict clinical usefulness from preclinical data.


   FOOTNOTES
 
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

1 Supported by NIH Grant CA78554 (to T. S. L.) and Cancer Center Core Grant CA46592. Back

2 To whom requests for reprints should be addressed, at Department of Radiation Oncology, University of Michigan, 1331 East Ann Street, Ann Arbor, MI 48109-0582. Phone: (734) 647-9955; Fax: (734) 763-7371; E-mail: tsl{at}umich.edu Back

3 The abbreviations used are: dFdCyd, 2',2'-difluoro-2'-deoxycytidine; DEVD, Z-Asp-Glu-Val-Asp-fluoromethylketone; zVAD, benzyloxycarbonyl-Val-Ala-Asp-fluoromethylketone. Back

Received 8/24/00; revised 10/16/00; accepted 11/15/00.


   REFERENCES
Top
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 

  1. Kelly K. The role of single-agent Gemcitabine in the treatment of non-small-cell lung cancer.. Ann. Oncol., 10: S53-S56, 1999.
  2. Sandler A., Ettinger D. Gemcitabine: single-agent and combination therapy in non-small cell lung cancer.. Oncologist, 4: 241-251, 1999.[Abstract/Free Full Text]
  3. Lawrence T., Eisbruch A., McGinn C., Fields M., Shewach D. Radiosensitization by Gemcitabine.. Oncology (Basel), 13: 55-60, 1999.
  4. Kroep J., Pinedo H., van Groeningen C., Peters G. Experimental drugs and drug combinations in pancreatic cancer.. Ann. Oncol., 10: 234-238, 1999.
  5. Huang P., Ballal K., Plunkett W. Biochemical characterization of the protein activity responsible for high molecular weight DNA fragmentation during drug-induced apoptosis.. Cancer Res., 57: 3407-3414, 1997.[Abstract/Free Full Text]
  6. Dole M., Nunez G., Merchant A., Maybaum J., Rode C., Bloch C., Castle V. bcl-2 protein inhibits chemotherapy-induced apoptosis in neuroblastoma.. Cancer Res., 54: 3253-3259, 1994.[Abstract/Free Full Text]
  7. Kamesaki S., Kamesaki H., Jorgensen T., Tanizawa A., Pommier Y., Cossman J. bcl-2 protein inhibits etoposide-induced apoptosis through its effects on events subsequent to topoisomerase II-induced DNA strand breaks and their repair.. Cancer Res., 53: 4251-4256, 1993.[Abstract/Free Full Text]
  8. Lowe S., Ruley H., Jacks T., Housman D. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents.. Cell, 74: 947-967, 1993.[CrossRef][Medline]
  9. Fraser A., Evan G. A license to kill.. Cell, 85: 781-784, 1996.[CrossRef][Medline]
  10. Martin S., Green D. Protease activation during apoptosis: death by a thousand cuts.. Cell, 82: 349-352, 1995.[CrossRef][Medline]
  11. Lawrence T., Davis M., Maybaum J., Mukhopadhay S., Stetson P., Normolle D., McKeever P., Ensminger W. The potential superiority of bromodeoxyuridine to iododeoxyuridine as a radiation sensitizer in the treatment of colorectal cancer.. Cancer Res., 52: 3698-3704, 1992.[Abstract/Free Full Text]
  12. Fertil B., Dertinger H., Courdi A., Malaise E. Mean inactivation dose: a useful concept for intercomparison of human cell survival curves.. Radiat. Res., 99: 73-84, 1984.[Medline]
  13. Naida J., Davis M., Lawrence T. The effect of activation of wild type p53 function on fluoropyrimidine-mediated radiosensitization.. Int. J. Radiat. Oncol. Biol. Phys., 41: 675-680, 1998.[CrossRef][Medline]
  14. Chen H., Zhang J., Ling C. Transfected c-myc and c-Ha-ras modulate radiation-induced apoptosis in rat embryo cells.. Radiat. Res., 139: 307-315, 1994.[CrossRef][Medline]
  15. Dewey W., Ling C., Meyn R. Radiation-induced apoptosis: relevance to radiotherapy.. Int. J. Radiat. Oncol. Biol. Phys., 33: 781-796, 1995.[CrossRef][Medline]
  16. Brown J., Wouters B. Apoptosis, p53, and tumor cell sensitivity to anticancer agents.. Cancer Res., 59: 1391-1399, 1999.[Abstract/Free Full Text]
  17. Huang P., Robertson L., Wright S., Plunkett W. High molecular weight DNA fragmentation: a critical event in nucleoside analogue-induced apoptosis in leukemia cells.. Clin. Cancer Res., 1: 1005-1013, 1995.[Abstract]
  18. Chen M., Quintans J., Fuks Z., Thompson C., Kufe D., Weichselbaum R. Suppression of Bcl-2 messenger RNA production may mediate apoptosis after ionizing radiation, tumor necrosis factor {alpha}, and ceramide.. Cancer Res., 55: 991-994, 1995.[Abstract/Free Full Text]
  19. Chinnaiyan A., Prasad U., Shankar S., Hamstra D., Shanaiah M., Chenevert T., Ross B., Rehemtulla A. Combined effect of tumor necrosis factor-related apoptosis-inducing ligand and ionizing radiation in breast cancer therapy.. Proc. Natl. Acad. Sci. USA, 97: 1754-1759, 2000.[Abstract/Free Full Text]
  20. Green D. Apoptotic pathways: the roads to ruin.. Cell, 94: 695-698, 1998.[CrossRef][Medline]
  21. Shewach D., Hahn T., Chang E., Hertel L., Lawrence T. Metabolism of 2',2'-difluoro-2'-deoxycytidine and radiation sensitization of human colon carcinoma cells.. Cancer Res., 54: 3218-3223, 1994.[Abstract/Free Full Text]
  22. Lawrence T., Chang E., Hahn T., Shewach D. Delayed radiosensitization of human colon carcinoma cells after a brief exposure to 2',2'-difluoro-2'-deoxycytidine (Gemcitabine).. Clin. Cancer Res., 3: 777-782, 1997.[Abstract]
  23. Chen M., Hough A., Lawrence T. The role of p53 in Gemcitabine-mediated cytotoxicity and radiosensitization.. Cancer Chemother. Pharmacol., 45: 369-374, 2000.[CrossRef][Medline]
  24. Eisbruch A., Shewach D., Bradford C., Littles J., Teknos T., Chepeha D., Marentette L., Terrell J., Hogikyan N., Dawson L., Urba S., Wolf G., Lawrence T. Radiation concurrent with gemcitabine for locally advanced head and neck cancer: a Phase I trial and intracellular drug incorporation study.J Clin. Oncol., in press 2001.
  25. McGinn C., Smith D., Szarka C., Pinover W., Loehrer P., Morphis J., Nicol S., Shewach D., Lawrence T., O’Dwyer P. A Phase I study of Gemcitabine in combination with radiation therapy in patients with localized unresectable pancreatic cancer.. Proc. Am. Soc. Clin. Oncol., 17: 264A 1998.

Commentary

The Clinical Implications of Gemcitabine Radiosensitization
Todd H. Doyle, Francoise Mornex, and W. Gillies McKenna
Clin. Cancer Res. 2001 7: 226-228. [Full Text] [PDF]



This article has been cited by other articles:


Home page
 Mol. Pharmacol.Home page
M. J. Cariveau, X. Tang, X.-L. Cui, and B. Xu
Characterization of an NBS1 C-Terminal Peptide That Can Inhibit Ataxia Telangiectasia Mutated (ATM)-Mediated DNA Damage Responses and Enhance Radiosensitivity
Mol. Pharmacol., August 1, 2007; 72(2): 320 - 326.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
S. A. Flanagan, B. W. Robinson, C. M. Krokosky, and D. S. Shewach
Mismatched nucleotides as the lesions responsible for radiosensitization with gemcitabine: a new paradigm for antimetabolite radiosensitizers
Mol. Cancer Ther., June 1, 2007; 6(6): 1858 - 1868.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
F. Y. Feng, C. A. Lopez, D. P. Normolle, S. Varambally, X. Li, P. Y. Chun, M. A. Davis, T. S. Lawrence, and M. K. Nyati
Effect of Epidermal Growth Factor Receptor Inhibitor Class in the Treatment of Head and Neck Cancer with Concurrent Radiochemotherapy In vivo
Clin. Cancer Res., April 15, 2007; 13(8): 2512 - 2518.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
S. Bonnaud, C. Niaudet, G. Pottier, M.-H. Gaugler, J. Millour, J. Barbet, L. Sabatier, and F. Paris
Sphingosine-1-Phosphate Protects Proliferating Endothelial Cells from Ceramide-Induced Apoptosis but not from DNA Damage-Induced Mitotic Death
Cancer Res., February 15, 2007; 67(4): 1803 - 1811.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
C. Bianco, E. Giovannetti, F. Ciardiello, V. Mey, S. Nannizzi, G. Tortora, T. Troiani, F. Pasqualetti, G. Eckhardt, M. de Liguoro, et al.
Synergistic Antitumor Activity of ZD6474, An Inhibitor of Vascular Endothelial Growth Factor Receptor and Epidermal Growth Factor Receptor Signaling, with Gemcitabine and Ionizing Radiation against Pancreatic Cancer
Clin. Cancer Res., December 1, 2006; 12(23): 7099 - 7107.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
P. Y. Chun, F. Y. Feng, A. M. Scheurer, M. A. Davis, T. S. Lawrence, and M. K. Nyati
Synergistic Effects of Gemcitabine and Gefitinib in the Treatment of Head and Neck Carcinoma
Cancer Res., January 15, 2006; 66(2): 981 - 988.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
M. A. Morgan, L. A. Parsels, J. D. Parsels, A. K. Mesiwala, J. Maybaum, and T. S. Lawrence
Role of Checkpoint Kinase 1 in Preventing Premature Mitosis in Response to Gemcitabine
Cancer Res., August 1, 2005; 65(15): 6835 - 6842.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
D. A. Fennell
Caspase Regulation in Non-Small Cell Lung Cancer and its Potential for Therapeutic Exploitation
Clin. Cancer Res., March 15, 2005; 11(6): 2097 - 2105.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
L. Xu, D. Yang, S. Wang, W. Tang, M. Liu, M. Davis, J. Chen, J. M. Rae, T. Lawrence, and M. E. Lippman
(-)-Gossypol enhances response to radiation therapy and results in tumor regression of human prostate cancer
Mol. Cancer Ther., February 1, 2005; 4(2): 197 - 205.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
B. Pauwels, A. E.C. Korst, F. Lardon, and J. B. Vermorken
Combined Modality Therapy of Gemcitabine and Radiation
Oncologist, January 1, 2005; 10(1): 34 - 51.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
T. Cook, Z. Wang, S. Alber, K. Liu, S. C. Watkins, Y. Vodovotz, T. R. Billiar, and D. Blumberg
Nitric Oxide and Ionizing Radiation Synergistically Promote Apoptosis and Growth Inhibition of Cancer by Activating p53
Cancer Res., November 1, 2004; 64(21): 8015 - 8021.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
Z. Wang, T. Cook, S. Alber, K. Liu, I. Kovesdi, S. K. Watkins, Y. Vodovotz, T. R. Billiar, and D. Blumberg
Adenoviral Gene Transfer of the Human Inducible Nitric Oxide Synthase Gene Enhances the Radiation Response of Human Colorectal Cancer Associated with Alterations in Tumor Vascularity
Cancer Res., February 15, 2004; 64(4): 1386 - 1395.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
M. K. Nyati, D. Maheshwari, S. Hanasoge, A. Sreekumar, S. D. Rynkiewicz, A. M. Chinnaiyan, W. R. Leopold, S. P. Ethier, and T. S. Lawrence
Radiosensitization by Pan ErbB Inhibitor CI-1033 in Vitro and in Vivo
Clin. Cancer Res., January 15, 2004; 10(2): 691 - 700.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
T. H. Doyle, F. Mornex, and W. G. McKenna
The Clinical Implications of Gemcitabine Radiosensitization
Clin. Cancer Res., February 1, 2001; 7(2): 226 - 228.
[Full Text]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lawrence, T. S.
Right arrow Articles by Rehemtulla, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lawrence, T. S.
Right arrow Articles by Rehemtulla, A.
Related Collections
Right arrowCommentary

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Cell Growth & Differentiation